Targeted cancer immunotherapy

Current Opinion in Pharmacology

Volumn 13, Issue 4, 2013, Pages 504-510

  Zigler, Maya ^a   Shir, Alexei ^a   Levitzki, Alexander ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; DENDRITIC CELL VACCINE; DOXORUBICIN; MONOCLONAL ANTIBODY; ONAMELATUCEL L; RINDOPEPIMUT;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; DRUG EFFICACY; DRUG TARGETING; HUMAN; IMMUNOSURVEILLANCE; MOLECULARLY TARGETED THERAPY; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SOLID TUMOR; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY;

EID: 84885949797     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2013.04.003     Document Type: Review

References (60)

1. Ehrlich P: Ueber den jetzigen Stand der Karzinomforschung. Ned Tijdschr Geneeskd 1909:273-290.
2. Burnet M: Cancer: a biological approach. III. Viruses associated with neoplastic conditions. IV. Practical applications. Br Med J 1957, 1:841-847.
3. Dunn GP, Old LJ, Schreiber RD: The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004, 21:137-148. (Pubitemid 39094044)
4. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ: Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011, 29:235-271.
5. Stewart TJ, Abrams SI: How tumours escape mass destruction. Oncogene 2008, 27:5894-5903.
6. Vanneman M, Dranoff G: Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 2012, 12:237-251.
7. Cohen N, Kravchenko-Balasha N, Klein S, Levitzki A: Heterogeneity of gene expression in murine squamous cell carcinoma development - the same tumor by different means. PLoS ONE 2013, 8(3):e57748.
8. Stewart TJ, Smyth MJ: Improving cancer immunotherapy by targeting tumor-induced immune suppression. Cancer Metastasis Rev 2011, 30:125-140.
9. Beck A, Wurch T, Bailly C, Corvaia N: Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 2010, 10:345-352.
10. Golay J, Introna M: Mechanism of action of therapeutic monoclonal antibodies: promises and pitfalls of in vitro and in vivo assays. Arch Biochem Biophys 2012, 526: 146-153.
11. Weiner LM, Surana R, Wang S: Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 2010, 10:317-327.
12. Dougan M, Dranoff G: Immune therapy for cancer. Annu Rev Immunol 2009, 27:83-117.
13. Scott AM, Allison JP, Wolchok JD: Monoclonal antibodies in cancer therapy. Cancer Immun 2012, 12:14.
14. Christiansen J, Rajasekaran AK: Biological impediments to monoclonal antibody-based cancer immunotherapy. Mol Cancer Ther 2004, 3:1493-1501. (Pubitemid 39562594)
15. Pillay V, Gan HK, Scott AM: Antibodies in oncology. N Biotechnol 2011, 28:518-529.
16. Sadelain M, Riviere I, Brentjens R: Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer 2003, 3:35-45. (Pubitemid 37328885)
17. June CH: Principles of adoptive T cell cancer therapy. J Clin Invest 2007, 117:1204-1212. (Pubitemid 46718405)
18. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME: Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008, 8:299-308. (Pubitemid 351430867)
19. Eshhar Z: Tumor-specific T-bodies: towards clinical application. Cancer Immunol Immunother 1997, 45:131-136. (Pubitemid 27521442)
20. Curran KJ, Pegram HJ, Brentjens RJ: Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions. J Gene Med 2012, 14:405-415.
21. Morgan RA, Johnson LA, Davis JL, Zheng Z, Woolard KD, Reap EA, Feldman SA, Chinnasamy N, Kuan CT, Song H et al.: Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum Gene Ther 2012, 23:1043-1053.
22. van Loenen MM, de Boer R, Hagedoorn RS, Jankipersadsing V, Amir AL, Falkenburg JH, Heemskerk MH: Multi-cistronic vector encoding optimized safety switch for adoptive therapy with Tcell receptor-modified T cells. Gene Ther 2013 Advanced online publication 31 January 2013 http://dx.doi.org/10.1038/gt.2013.4 Epub ahead of print.
23. Curran KJ, Pegram HJ, Brentjens RJ: Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions. J Gene Med 2012, 14:405-415.
24. Gajewski TF: Cancer immunotherapy. Mol Oncol 2012, 6:242-250.
25. Almand B, Resser JR, Lindman B, Nadaf S, Clark JI, Kwon ED, Carbone DP, Gabrilovich DI: Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 2000, 6:1755-1766. (Pubitemid 30305068)
26. Benencia F, Sprague L, McGinty J, Pate M, Muccioli M: Dendritic cells the tumor microenvironment and the challenges for an effective antitumor vaccination. J Biomed Biotechnol 2012, 2012:425476.
27. Monjazeb AM, Hsiao HH, Sckisel GD, Murphy WJ: The role of antigen-specific and non-specific immunotherapy in the treatment of cancer. J Immunotoxicol 2012, 9:248-258.
28. Del Vecchio CA, Li G, Wong AJ: Targeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomas. Expert Rev Vaccines 2012, 11:133-144.
29. Babu R, Adamson DC: Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIIIpositive glioblastoma. Core Evid 2012, 7:93-103.
30. Xu L, Xu W, Qiu S, Xiong S: Enrichment of CCR6+Foxp3+ regulatory T cells in the tumor mass correlates with impaired CD8+ T cell function and poor prognosis of breast cancer. Clin Immunol 2010, 135:466-475.
31. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M et al.: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004, 10:942-949. (Pubitemid 39273735)
32. Elkord E, Alcantar-Orozco EM, Dovedi SJ, Tran DQ, Hawkins RE, Gilham DE: T regulatory cells in cancer: recent advances and therapeutic potential. Expert Opin Biol Ther 2010, 10:1573-1586.
33. Litzinger MT, Fernando R, Curiel TJ, Grosenbach DW, Schlom J, Palena C: IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. Blood 2007, 110:3192-3201. (Pubitemid 350106311)
34. Rech AJ, Mick R, Martin S, Recio A, Aqui NA, Powell DJ Jr, Colligon TA, Trosko JA, Leinbach LI, Pletcher CH et al.: CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients. Sci Transl Med 2012, 4:134ra162.
35. Morita R, Hirohashi Y, Sato N: Depletion of Tregs in vivo: a promising approach to enhance antitumor immunity without autoimmunity. Immunotherapy 2012, 4:1103-1105.
36. Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012, 12:252-264.
37. Engelhardt JJ, Sullivan TJ, Allison JP: CTLA-4 overexpression inhibits T cell responses through a CD28-B7-dependent mechanism. J Immunol 2006, 177:1052-1061. (Pubitemid 44036607)
38. Schneider H, Downey J, Smith A, Zinselmeyer BH, Rush C, Brewer JM, Wei B, Hogg N, Garside P, Rudd CE: Reversal of the TCR stop signal by CTLA-4. Science 2006, 313:1972-1975. (Pubitemid 44498006)
39. Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP: Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti- CTLA-4 antibodies. J Exp Med 2009, 206:1717-1725.
40. Wolchok JD, Saenger Y: The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. Oncologist 2008, 13(Suppl 4):2-9.
41. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC et al.: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
42. Robert C, Thomas L, Bondarenko I, O'Day SMDJ, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ et al.: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011, 364:2517-2526.
43. Zhou G, Levitsky H: Towards curative cancer immunotherapy: overcoming posttherapy tumor escape. Clin Dev Immunol 2012, 2012:124187.
44. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC et al.: Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000, 192:1027-1034.
45. Wang L, Pino-Lagos K, de Vries VC, Guleria I, Sayegh MH, Noelle RJ: Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells. Proc Natl Acad Sci U S A 2008, 105:9331-9336.
46. Chen DS, Irving BA, Hodi FS: Molecular pathways: nextgeneration immunotherapy - inhibiting programmed deathligand 1 and programmed death-1. Clin Cancer Res 2012, 18:6580-6587.
47. Kirkwood JM, Butterfield LH, Tarhini AA, Zarour H, Kalinski P, Ferrone S: Immunotherapy of cancer in 2012. CA Cancer J Clin 2012, 62:309-335.
48. Sznol MFSH, Margolin K, McDermott DF, Ernstoff MS, Kirkwood JM, Wojtaszek C, Feltquate D, Logan T: Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA). ASCO Annual Meeting Proceedings (Post-Meeting Edition), No 15S (May 20 Supplement), 2008: 3007. J Clin Oncol 2008, 26(Suppl) [abstr 3007].
49. Khubchandani S, Czuczman MS, Hernandez-Ilizaliturri FJ: Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies. Curr Opin Investig Drugs 2009, 10:579-587.
50. Singer K, Gottfried E, Kreutz M, Mackensen A: Suppression of Tcell responses by tumor metabolites. Cancer Immunol Immunother 2011, 60:425-431.
51. De Santo C, Serafini P, Marigo I, Dolcetti L, Bolla M, Del Soldato P, Melani C, Guiducci C, Colombo MP, Iezzi M et al.: Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proc Natl Acad Sci U S A 2005, 102:4185-4190. (Pubitemid 40388577)
52. Yen MC, Lin CC, Chen YL, Huang SS, Yang HJ, Chang CP, Lei HY, Lai MD: A novel cancer therapy by skin delivery of indoleamine 2,3-dioxygenase siRNA. Clin Cancer Res 2009, 15:641-649.
53. Zheng X, Koropatnick J, Li M, Zhang X, Ling F, Ren X, Hao X, Sun H, Vladau C, Franek JA et al.: Reinstalling antitumor immunity by inhibiting tumor-derived immunosuppressive molecule IDO through RNA interference. J Immunol 2006, 177:5639-5646. (Pubitemid 44527639)
54. Andersen MH: The specific targeting of immune regulation: Tcell responses against Indoleamine 2,3-dioxygenase. Cancer Immunol Immunother 2012, 61:1289-1297.
55. Yu H, Kortylewski M, Pardoll D: Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007, 7:41-51. (Pubitemid 46020826)
56. Lee H, Pal SK, Reckamp K, Figlin RA, Yu H: STAT3: a target to enhance antitumor immune response. Curr Top Microbiol Immunol 2011, 344:41-59.
57. Yue P, Turkson J: Targeting STAT3 in cancer: how successful are we? Expert Opin Investig Drugs 2009, 18:45-56.
58. Galluzzi L, Senovilla L, Zitvogel L, Kroemer G: The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012, 11:215-233.
59. Bruchard M, Mignot G, Derangere V, Chalmin F, Chevriaux A, Vegran F, Boireau W, Simon B, Ryffel B, Connat JL et al.: Chemotherapy-triggered cathepsin B release in myeloidderived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med 2012, 19:57-64.
60. Shir A, Ogris M, Roedl W, Wagner E, Levitzki A: EGFR-homing dsRNA activates cancer-targeted immune response and eliminates disseminated EGFR-overexpressing tumors in mice. Clin Cancer Res 2011, 17:1033-1043.